Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

FuturHealth vs InstaRX

FuturHealth
Graded #215

Higher grade

vs+1.7999999999999972
InstaRX
Graded #250

Lower grade

The verdict

FuturHealth takes it — 65.6/100 to 63.8/100, but only just.

FuturHealth grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. FuturHealth Inc. is a San Diego-based telehealth weight management brand offering brand-name Ozempic, Wegovy (injection AND oral pill), Mounjaro, Zepbound, and Foundayo (orforglipron oral pill, added InstaRX is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
60
60
Dose & formulationFuturHealth +17
81
64
Clinical oversightInstaRX +5
67
72
Labs & monitoringFuturHealth +9
61
52
FulfillmentInstaRX +16
62
78
Contract termsEven
55
55
FuturHealth · left barInstaRX · right bar

The numbers

MetricFuturHealthInstaRX
WeighScore65.6/10063.8/100
GradeCC
Scorecard rank#215#250
Semaglutide$199/mo (compounded)$199/mo (starting dose, compounded)
TirzepatideNot disclosed$199/mo (starting dose, compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
FuturHealth

Graded #215 · C

Strengths

  • LegitScript Certified and HITRUST Certified
  • Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
  • Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
  • Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths

Where it loses points

  • Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
  • BBB complaints describe recurring charges without medication received — confirm cancellation flow first
  • Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
  • Pricing not shown until after the qualification questionnaire or portal login
  • Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber
InstaRX

Graded #250 · C

Strengths

  • Available in all 50 states plus DC
  • Manage GLP-1, anti-aging peptides, and sexual-health medications on one account
  • Offers both compounded semaglutide and compounded tirzepatide
  • Independent provider group (Dr Telx) named in the Terms of Service

Where it loses points

  • No per-dose or monthly pricing published — only a "$199 to get started" hook; you can't compare costs before intake
  • No LegitScript, HIPAA, or NABP accreditation shown on public pages
  • Compounding pharmacy not named — only "U.S. pharmacies"
  • Terms of Service reads like generic boilerplate, including copy-paste language about women's health issues — suggests low template hygiene
  • Delaware governing law for disputes despite a California corporate address

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard